Tharimmune receives regulatory feedback from EMA for TH104 program
Tharimmune (THAR) received feedback from a Scientific Advice meeting with the European Medicines Agency that included guidance on a planned ...
Renal & Urology News7d
Novel Drug Shows Early Efficacy in Treating Pruritus
Targeting the kappa opioid receptor with an agonist is a new pharmacy strategy for treating moderate to severe CKD-associated ...
Medscape8d
Upadacitinib Effective Long Term for AD in Adolescents
An analysis of three phase 3 trials reported relief with upadacitinib through 76 weeks in adolescents with AD.
Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
Eli Lilly's Ebglyss improves skin and itch symptoms in eczema patients, including Dupixent-treated cases, with positive Phase ...
MedPage Today21d
A New Blueprint for Pruritus Care
A recent literature review presents a range of causes and treatments for chronic pruritus, including more novel options and a disease schematic for clinical decision support. The review has been ...
Business Wire26d
Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis
The regulatory designation is based on the positive interim analysis of the Phase 2b VANTAGE study which showed statistically significant improvement versus placebo in pruritus for patients ...
Yahoo Finance26d
Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis
In June, Mirum announced positive interim results from the Phase 2b VANTAGE study showing statistically significant improvement in pruritus as well as meaningful reductions in serum bile acids and ...